7.02

1.15% 0.08

After Hours: 7.02

Adverum Biotechnologies Inc (ADVM)

Overview News Price History Option Chain Financials Discussions Forecast

Adverum Biotechnologies Inc stock is traded at $7.02, with a volume of 76,161. It is up +1.15% in the last 24 hours and up +1.15% over the past month. Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Previous Close:

$6.94

Open:

$6.9

24h Volume:

76,161

Relative Volume:

0.25

Market Cap:

$145.61M

Revenue:

Net Income/Loss:

$-117.17M

P/E Ratio:

-5.2782

EPS:

-1.33

Net Cash Flow:

$-91.71M

1W Performance:

+2.03%

1M Performance:

+1.15%

6M Performance:

-50.35%

1Y Performance:

-53.20%

1-Day Range:

$6.90

$7.11

1-Week Range:

$6.52

$7.11

52-Week Range:

$6.38

$29.70

Adverum Biotechnologies Inc Stock (ADVM) Company Profile

Name

Adverum Biotechnologies Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(650) 649-1004

Address

100 CARDINAL WAY, REDWOOD CITY, CA

Employee

121

Twitter

@adverumbio

Next Earnings Date

2024-08-16

Latest SEC Filings

ADVM's Discussions on Twitter

Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-07-22	Upgrade	Truist	Hold → Buy
Jul-23-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-03-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Apr-29-21	Downgrade	Chardan Capital Markets	Buy → Neutral
Apr-29-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Apr-29-21	Downgrade	Truist	Buy → Hold
Dec-16-20	Initiated	UBS	Neutral
Nov-12-20	Upgrade	Raymond James	Underperform → Mkt Perform
Jun-26-20	Downgrade	Raymond James	Mkt Perform → Underperform
May-13-20	Initiated	RBC Capital Mkts	Outperform
May-05-20	Upgrade	SunTrust	Hold → Buy
Apr-28-20	Initiated	Goldman	Buy
Mar-16-20	Initiated	SVB Leerink	Outperform
Feb-10-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-10-20	Upgrade	Chardan Capital Markets	Neutral → Buy
Oct-15-19	Reiterated	Chardan Capital Markets	Neutral
Sep-13-19	Reiterated	Chardan Capital Markets	Neutral
Jun-14-19	Resumed	Raymond James	Mkt Perform
Nov-02-18	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-02-18	Downgrade	SunTrust	Buy → Hold
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Aug-30-18	Initiated	SunTrust	Buy
Feb-15-18	Resumed	Piper Jaffray	Overweight
Oct-12-17	Initiated	Raymond James	Outperform

View All

Adverum Biotechnologies Inc Stock (ADVM) Latest News

Sep 27, 2024

Wall Street SWOT: Adverum Biotechnologies stock faces pivotal year amid trials - Investing.com

Sep 27, 2024

Mizuho Initiates Coverage of Adverum Biotechnologies (ADVM) with Buy Recommendation - MSN

Sep 27, 2024

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $28.17 Average Target Price from Analysts - MarketBeat

Sep 27, 2024

Sep 24, 2024

(ADVM) Trading Advice - Stock Traders Daily

Sep 24, 2024

Logos Global Management LP Sells 1,083,333 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat

Sep 24, 2024

Adverum Biotechnologies (NASDAQ:ADVM) & CRISPR Therapeutics (NASDAQ:CRSP) Head to Head Comparison - Defense World

Sep 24, 2024

Sep 19, 2024

Adverum Biotechnologies (NASDAQ:ADVM) Share Price Passes Below Two Hundred Day Moving Average of $9.52 - MarketBeat

Sep 19, 2024

Sep 13, 2024

(ADVM) Investment Analysis - Stock Traders Daily

Sep 13, 2024

Sep 05, 2024

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 05, 2024

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sep 05, 2024

Sep 04, 2024

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences - ForexTV.com

Sep 04, 2024

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences - GlobeNewswire

Sep 04, 2024

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences - Yahoo Finance

Sep 04, 2024

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences - StockTitan

Sep 04, 2024

Sep 03, 2024

Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High? - Yahoo Finance

Sep 03, 2024

Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High? - Nasdaq

Sep 03, 2024

Sep 02, 2024